Introduction
============

Within the group of mitochondrial diseases or more specifically, OXPHOS disorders, isolated mitochondrial complex III (CIII) deficiencies are among the least frequently diagnosed. It is possible that these deficits are not rarer than those of the other complexes, but their diagnosis may be more difficult due to the lack of histological and biochemical hallmarks in skeletal muscle biopsies, e.g., no COX negative or ragged red fibers ([@B23]). Also, different protocols used in different labs to measure CIII enzymatic activity can also introduce some bias to detect defects ([@B52]). Typical to mitochondrial syndromes, CIII defects are associated with a wide range of clinical presentations, the only common feature being the reduced ubiquinol:cytochrome c oxidoreductase enzymatic activity measured in samples from the subjects under study. The defective factor responsible for CIII malfunction and thus, the molecular pathogenic mechanisms are also widely variable.

Complex III or cytochrome bc1 complex forms the central part of the mitochondrial respiratory chain, oxidizing coenzyme Q and reducing cytochrome c while pumping protons from the matrix to the intermembrane space through the so-called Q-cycle mechanism ([@B17]). Mammalian CIII is a multiheteromeric enzyme composed of eleven different subunits ([@B68]), one encoded by mitochondrial DNA (mtDNA) and ten by nuclear genes. These eleven subunits constitute the monomeric module of a symmetric dimer (CIII~2~), which constitutes the functionally active form of the enzyme. The complex is embedded in the mitochondrial inner membrane, spanning from the matrix to the inter-membrane space. The crystal structure ([@B78]; [@B41]) differs from the ones of yeast ([@B39]) and chicken ([@B83]) only because it contains one additional subunit. This extra subunit (Subunit 9) is just the mitochondrial targeting sequence peptide of the Rieske Fe-S protein, which is incorporated into the complex after its cleavage during import into the organelle ([@B15]). Three of the 11 subunits contain the catalytic centers: cytochrome b (MT-CYB), cytochrome c1 (CYC1) and the Rieske protein (UQCRFS1). Cytochrome b contains two heme moieties, the low potential (b~L~) and the high potential (b~H~) heme b; CYC1 binds a c-type heme group and the Rieske iron-sulfur protein contains a 2Fe-2S cluster. The exact function of the other eight supernumerary subunits (UQCRC1, UQCRC2, UQCRH, UQCRB, UQCRQ, Subunit 9, UQCR10 and UQCR11) remains to be established ([@B77]).

The proteins needed for transcription and translation of MT-CYB, as well as CIII assembly factors, are all encoded by nuclear genes.

Cytochrome bc1 assembly has been mainly studied in the yeast *Saccharomyces cerevisiae.* Yeast deletion mutants have proved to be an extremely useful tool to discover proteins involved in CIII and CIV biogenesis. By using yeast as a model organism, a great deal of CIV assembly factors have been discovered during the last two decades, and the assembly of this enzyme is known in mechanistic detail ([@B55]; [@B71]). Although investigation on CIII biogenesis has been far less assiduous, models of CIII assembly in yeast have been developed in the last years ([@B82], [@B79], [@B81]; [@B32], [@B34]; [@B37]). According to these models, the different structural subunits start gathering inside several subcomplexes that afterward join to form a pre-CIII. The complex finally matures and becomes active with the addition of the Rieske protein, which is the second to last subunit to be incorporated. A complete understanding on how this incorporation occurs has already been achieved in yeast ([@B75]). Thus, in addition to the structural subunits, another set of proteins are involved in the process acting as chaperones, which bind individual subunits or assembly intermediates to stabilize them, or as assembly factors, who act to incorporate subunits during the pathway ([@B70]). CIII assembly in humans is deemed to be similar to that in yeast (**Figure [1](#F1){ref-type="fig"}**), given the structural similarity between yeast and mammalian CIII and because several orthologs of yeast assembly factors have been identified in humans as well ([@B65]; [@B67]; [@B72]; [@B76]). However, mechanistic details have been experimentally proven only for a few steps of human CIII assembly. The initial step is the release of MT-CYB from the mitoribosome and its insertion into the mitochondrial inner membrane, a process that requires two assembly factors, UQCC1 and UQCC2 ([@B72]). A much later step has also been defined in humans, consisting in the incorporation of the Rieske protein (UQCRFS1), operated by the assembly factor, BCS1L, into a nearly complete dimeric but inactive pre-complex III (pre-CIII~2~; [@B26]; [@B38]; [@B31]). The exact mechanism has not been studied in detailed in human systems, but the evidences point to a very similar process as the one in yeast mitochondria. However, there is still very limited information about the intermediate steps, i.e., how the pre-CIII~2~ stage is achieved.

![**Human complex III assembly model**. The model is constructed by homology with the available data for *S. cerevisiae* ([@B79], [@B80],[@B81]; [@B9]; [@B32], [@B34]; [@B75]; [@B19]; [@B70]; [@B37]). The names of the proteins mutated in CIII-deficiency cases are in red. First, MT-CYB is translated in the mitochondrial ribosomes to which UQCC1 and UQCC2 are bound to the exit tunnel, activating its synthesis. The UQCC1-UQCC2 complex remains bound to MT-CYB once it is completely synthesized and incorporated to the mitochondrial inner membrane. Once low-potential heme b (b~L~) is inserted into the catalytic center of cytochrome b, UQCC3 binds to it and then the high potential heme b (b~H~) is incorporated. The UQCC1-UQCC2 dimer is released when UQCRB and UQCRQ bind to MT-CYB, to form the early-stage CIII intermediary, so that UQCC1-UQCC2 dimer becomes available to activate translation of new MT-CYB by binding to the mitoribosome. This system provides a way of regulating MT-CYB translation related to its assembly into CIII. After the formation of the early intermediate MT-CYB+UQCRB+UQCRQ, additional subunits, i.e., UQCRC1, UQCRC2, and CYC1 are incorporated, followed by UQCRH and later UQCR10, to form pre-complex III (pre-CIII~2~). At this point, the complex is already dimeric, but the precise stage at which dimerization occurs is currently unknown. Finally, UQCRFS1 is translocated from the matrix into the inner mitochondrial membrane and is incorporated into pre-CIII~2~. In the matrix, UQCRFS1 is bound and stabilized by MZM1L. Finally the last subunit (UQCR11) joins the nascent complex, so that assembly is completed. TTC19 is necessary for the correct biogenesis of CIII~2~ in human mitochondria, but the step in which it intervenes is not known yet.](fgene-06-00134-g001){#F1}

Until 2008, mutations in only three genes were known to be associated with CIII deficiency ([@B13]; [@B27]). The first to be detected were in *MT-CYB* (OMIM 516020), initially described in the late 1990's ([@B5], [@B3],[@B4]; [@B20]; [@B43]). These were usually sporadic mutations causing myopathy and exercise intolerance. Then, mutations in the nuclear gene *BCS1L* were found in CIII-deficient patients ([@B21]). Defective BCS1L is still the most frequent cause of CIII-defective mitochondrial disease, as more than 25 different pathological mutations associated to very variable clinical presentations have been described (**Table [3](#T3){ref-type="table"}**). Finally, a mutation in the *UQCRB* gene was found in a subject with hepatopathy and CIII deficiency ([@B36]). Since then, the introduction of next generation sequencing (NGS) techniques and the identification of additional assembly factors in yeast ([@B18]; [@B8]; [@B32], [@B34]; [@B51]; [@B19]) corresponding to orthologs in humans, has led to the identification of seven more CIII-disease genes. Three encode CIII structural subunits: *UQCRQ* ([@B11]), *UQCRC2* ([@B56]), *CYC1* ([@B29]) whereas the remaining four encode assembly factors: *TTC19* ([@B30])*, LYRM7* ([@B40]), *UQCC2* ([@B72]) and *UQCC3* ([@B76]). All of the mutations in nuclear genes follow an autosomal recessive pattern of inheritance.

This review will describe in detail each of the nuclear-encoded proteins in which mutations have been found to be associated to CIII deficiency (summarized in **Table [1](#T1){ref-type="table"}**) in relation to their function and the clinical presentations of the patients suffering from this condition. In an attempt to explain the molecular pathological mechanisms found in the patients we will relate them to the role of the specific protein within the assembly process, bearing in mind that most of the information was obtained in the *S. cerevisiae* system.

###### 

Summary of the proteins encoded in the nuclear genome in which mutations have been associated to Mitochondrial Complex III Deficiency.

  Protein                   Yeast ortholog   Molecular role                                 OMIMnumber
  ------------------------- ---------------- ---------------------------------------------- ------------
  **Structural subunits**                                                                   
  UQCRB                     Qcr7             Supernumerary subunit                          191330
  UQCRQ                     Qcr8             Supernumerary subunit                          612080
  UQCRC2                    Qcr2 (Cor2)      Supernumerary subunit                          191329
  CYC1                      Cyt1             Catalytic subunit                              123980
  **Accessory factors**                                                                     
  TTC19                     --               Unknown                                        613814
  BCS1L                     Bcs1             UQCRFS1 translocase                            603647
  LYRM7/MZM1L               Mzm1             UQCRFS1chaperone                               615831
  UQCC2                     Cbp6             MT-CYB translational activator and chaperone   614461
  UQCC3                     Cbp4             MT-CYB chaperone                               --

Structural Subunits
===================

UQCRB
-----

The daughter of healthy consanguineous Turkish parents is the only known case of CIII deficiency caused by a mutation in the *UQCRB* gene, located on chromosome 8q22 (OMIM 191330). *UQCRB* encodes the human ubiquinone-binding protein of CIII (QP-C subunit or subunit VI; [@B36]). The girl was born and developed normally until 8 months of age when she presented with acute gastroenteritis. She showed liver enlargement and blood tests revealed mildly elevated hepatic enzymes, hypoglycemia, metabolic acidosis due to high blood lactate levels that increased during metabolic crises. Isolated CIII deficiency was detected in lymphocytes, skin fibroblasts and in a liver biopsy. Furthermore, the amount of cytochrome b was greatly reduced in mitochondria isolated from fibroblasts. The child was reported to have undergone good clinical recovery, with neither psychomotor nor other neurological impairment. Genetic analyses showed a homozygous 4-bp deletion (nucleotides 338--341) in exon 4 of the UQCRB gene, which predicts the synthesis of an abnormal amino acid stretch at the C-terminal end in a highly conserved portion of the protein. Both parents were heterozygous for the same mutation, which was absent in 55 control individuals.

UQCRB is the homolog of the yeast Qcr7 subunit, which is located in the matrix-inner mitochondrial membrane interphase and is deemed to interact with cytochrome b in early stages of the assembly pathway ([@B80]; **Figure [1](#F1){ref-type="fig"}**). Qcr7 incorporation is essential to stabilize hemylated cytochrome b ([@B37]). By analogy, UQCRB must be important for MT-CYB stability, which would explain the low amounts of b-type cytochrome found in the patient mitochondria.

UQCRQ
-----

*UQCRQ* is a nuclear gene located on chromosome 5q31, which encodes a 9.5 kDa structural subunit of CIII, UQCRQ, also termed subunit VII (OMIM 612080). A deleterious, autosomal recessive mutation consisting of a c.208C \> T transition in exon 2 of *UQCRQ*, determining a p.Ser45Phe amino acid change, was found in 25 affected members of a large consanguineous Israeli Bedouin kindred ([@B11]). All the affected individuals appeared normal at birth but showed delayed development during the first months of life, followed by the development of severe Leigh-like syndrome with profound mental and extrapyramidal signs. Reduced CIII activity was found in skeletal muscle of the probands. Albeit severe and early-onset, the clinical course was progressive, with some individuals still being alive in their thirties.

UQCRQ is embedded in the mitochondrial inner membrane, in close contact to MT-CYB deep in the CIII backbone structure ([@B41]). Its yeast homolog, Qcr8, was proposed to form the early cytochrome b subcomplex together with Qcr7 ([@B80]; **Figure [1](#F1){ref-type="fig"}**).

UQCRC2
------

Linkage analysis and whole-exome sequencing allowed the identification of a pathological mutation in the *UQCRC2* gene, located on chromosome 16p2, encoding the CIII Core 2 protein (also termed subunit II; OMIM 191329). The same homozygous nucleotide mutation, (c.547C\>T) leading to a p.Arg183Trp amino acid change, was found in three members of a Mexican consanguineous family ([@B56]). Right after birth, the children presented recurrent episodes of metabolic decompensation with lactic acidosis, hypoglycemia, hyperammonemia, and ketosis but no neurological impairment or severe developmental delay. In fact, the clinical presentation resembled that of the already reported UQCRB mutation (see above). The p.Arg183Trp predicts to disrupt the protein structure at its hydrophobic core, thus affecting CIII stability. In agreement with this prediction, the patient fibroblasts showed a twofold reduction of CIII activity and amount.

According to the CIII structure, Core 2 is facing the matrix in close interaction with core 1 (UQCRC1). In the most recent assembly model of the yeast bc1 complex, the core 2 subunit (Qcr2) is proposed to interact with CYC1 to form one of the assembly intermediates ([@B80]; **Figure [1](#F1){ref-type="fig"}**).

Cytochrome c1
-------------

Mutations in one of the nuclear-encoded catalytic subunits, CYC1 were proved to cause CIII deficiency in two unrelated patients with similar clinical course ([@B29]). The protein is a product of the *CYC1* gene, located on chromosome 8q24 (OMIM 123980). The son of first cousins of Lebanese origin was found to carry a homozygous c.288G\>T transversion, by whole-exome sequencing. The consequence of this change is the substitution of an invariant tryptophan residue in position 96 of the protein (p.Trp96Cys). The second patient, a Sri Lankan girl also born to consanguineous parents, carried another missense mutation in both alleles (c.643C\>T) which produces a p.Leu215Phe amino acid change. Sequence alignment of CYC1 from different species proved the total conservation of this residue throughout evolution. The main clinical feature in both patients was the recurrent episodes of metabolic failure, usually after minor infections, with hypo or hyperglycemia that was responsive to insulin treatment, and severe hyperlactatemia. In both, neurodegenerative lesions were detected by brain MRI whereas psychomotor regression during metabolic crises was followed by complete recovery and overall normal development.

Immunoblot analyses of fibroblasts and skeletal muscle from both patients showed low steady state levels of CYC1 and a CIII assembly defect. Furthermore, both mutations were predicted to disturb the protein structure, but showed to generate hypomorphic alleles since high copies of the mutant protein could rescue the respiratory defect either in a deletion yeast strain or in the patient cells.

Within CIII, CYC1 is anchored to the inner mitochondrial membrane, and its C-terminus, containing the heme moiety, faces the inter-membrane space. CYC1 receives the electrons from UQCRFS1 to then transfer them to the mobile electron carrier cytochrome c ([@B41]). In different yeast strains carrying deletions in structural subunits in which bc1 assembly is arrested, it was shown that CYC1 interacts with Core 1 and Core 2 ([@B79]). This led the Authors to conclude that the three subunits interact with each other early during CIII assembly ([@B80]; **Figure [1](#F1){ref-type="fig"}**). Considering the similarities in CIII structure and assembly, this would explain the low UQCRC1 and UQCRC2 levels found in the CYC1 mutated fibroblasts and skeletal muscle ([@B29]).

Accessory Proteins: Assembly Factors
====================================

TTC19
-----

*TTC19* (OMIM 613814), located on chromosome 17p12, encodes a protein shown to be involved in CIII biogenesis. The tetratricopeptide repeat domain-containing protein 19 (TTC19) is present in animals but absent in plants or yeast ([@B30]). The first cases of CIII deficiency associated to *TTC19* mutations were described in three patients from two unrelated Italian families with early-onset but slowly progressive encephalopathy, and in a fourth patient with late-onset but rapidly progressive neurological failure ([@B30]). Since the first cases were reported, other *TTC19* mutations have been published always associated with isolated CIII but with different clinical presentations. A progressive neurodegenerative disorder showing severe psychiatric signs and cerebellar disease was found in four Portuguese siblings born to consanguineous parents ([@B62]), Leigh syndrome was reported in a Hispanic child ([@B10]) and cerebellar ataxia in Japanese adult individuals ([@B59]; [@B46]). All the described cases (**Table [2](#T2){ref-type="table"}**) carried non-sense or frameshift mutations leading to a truncated protein and, at least in the first reported patient samples, to undetectable TTC19 levels ([@B30]). However, the clinical output may vary in age of onset, severity, and presence of psychiatric symptoms.

###### 

Summary of the clinical presentations and mutations in TTC19.

  Phenotype                                                                                                                          TTC19 mutation                  Reported in
  ---------------------------------------------------------------------------------------------------------------------------------- ------------------------------- -------------
  **Early onset**                                                                                                                                                    
  Slowly progressive cognitive impairment and ataxia                                                                                 p.Leu219Ter                     [@B30]
  Slowly progressive developmental delay and language regression, Leigh syndrome                                                     p.Trp186Ter/p.Gly322MetfsTer8   [@B10]
  Slowly progressive unsteady gait, learning difficulties, and behavioral alterations                                                p.Gln77ArgfsTer30               [@B53]
  **Late onset**                                                                                                                                                     
  Rapidly progressive neurological and psychiatric symptoms                                                                          p.Gln173Ter                     [@B30]
  Rapidly progressive psychiatric symptoms, ataxia and pyramidal signs                                                               p.Ala321fsTer8                  [@B62]
  Rapidly progressive spinocerebellar ataxia and cognitive impairment                                                                p.Gln277Ter                     [@B59]
  Cerebellar ataxia, spastic paraparesis, loss of deep sensation, mild frontal lobe dysfunction and transient psychiatric symptoms   p.Pro54AlafsTer48               [@B46]

TTC19 was shown to co-immunoprecipitate and co-migrate in Blue-Native Gel Electrophoresis (BNGE) with several CIII structural subunits, suggesting physical interaction. Although its exact function is currently unknown, a role as a chaperone in the first steps of CIII assembly is proposed for this protein, because a proportion of unassembled UQCRC1 and UQCRC2 were found in mutant muscle samples ([@B30]). In addition, a Ttc19-null *Drosophila melanogaster* model showed profound CIII deficiency associated to neurological impairment in adult individuals but, surprisingly, normal CIII activity in larvae, suggesting developmental control of CIII assembly in flies ([@B30]).

BCS1L
-----

Mutations in *BCS1L* on chromosome 2q35 (OMIM 603647) are still the most frequent cause of mitochondrial CIII isolated deficiency. BCS1L is a member of the AAA+ ([A]{.ul}TPases [a]{.ul}ssociated with diverse cellular [a]{.ul}ctivities) family of proteins. Yeast Bcs1 or human BCS1L are needed for the final steps of bc1 complex assembly, where the Rieske Fe-S protein (Rip1 or UQCRFS1) and the smallest subunit (Qcr10 or UQCR11) are incorporated into the pre-CIII~2~ to complete the process ([@B61]; [@B18]; [@B26]; [@B75]). Bcs1 is not exactly a chaperone, as it was demonstrated to act as a translocase of the Rieske Fe-S protein (Rip1), moving it from the matrix to the inner mitochondrial membrane through interaction with the Rip1 N-terminal domain and ATP hydrolysis ([@B75]; [@B19]). Bcs1 ATPase activity seems to be necessary not only for its function but also to couple the mitochondrial energy state to CIII biogenesis ([@B64]).

BCS1L mutations (**Figure [2](#F2){ref-type="fig"}**) are associated with a wide variety of clinical manifestations with different tissue involvement and disease progression (**Table [3](#T3){ref-type="table"}**), ranging from multivisceral GRACILE syndrome (growth retardation, aminoaciduria, cholestasis, iron overload, lactic acidosis, and early death; OMIM 603358; [@B74]; [@B49]; [@B42]); to congenital metabolic acidosis, neonatal proximal tubulopathy and/or liver failure with or without encephalopathy ([@B21]; [@B22]; [@B14]; [@B31]; [@B66]; [@B24]); to isolated severe mitochondrial encephalopathy ([@B26]); to milder phenotypes such as Björnstad syndrome (sensorineural hearing loss and pili torti; OMIM 262000; [@B38]; [@B69]), a neurological syndrome with long-term survival ([@B73]) or neuro-psychiatric manifestations ([@B2]). In contrast to the other BCS1L mutations, no CIII deficiency was originally reported for the GRACILE mutation, leading to p.Ser78Gly change which is part of the Finnish heritage disease repertoire ([@B25]). However, a more recent report demonstrated decreased CIII amount and activity in liver, kidney and heart of a GRACILE mutant patient ([@B44]). The other BCS1L mutations are indeed all associated with CIII deficiency, either isolated or in combination with reduced CIV and sometimes CI activities, with reduced amount of UQCRFS1 and with accumulation of unstable pre-CIII~2~ ([@B26]; [@B38]; [@B57]).

![**Schematic representation of human BCS1L**. Different coding exons and functional regions of the protein. TMD, trans-membrane domain; MTS: mitochondrial targeting sequence; IAS: import auxiliary sequence. Positions and amino acid changes of the pathological mutations described up to date are also depicted.](fgene-06-00134-g002){#F2}

###### 

Summary of the clinical presentations and mutations in BCS1L.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                            Phenotype                                                                                               BCS1L mutation                          Reported in
  ------------------------- ------------------------------------------------------------------------------------------------------- --------------------------------------- --------------------------
  **Purely Visceral**       GRACILE syndrome                                                                                        p.Ser78Glyp.\                           [@B74][@B42]
                                                                                                                                    Pro99Leu                                

                            Complex III deficiency, lactic acidosis, hepatopathy, developmental delay, sensorineural hearing loss   p.Thr50Ala                              [@B14]

                            GRACILE + CIII deficiency + neurological symptoms                                                       p.Arg56Ter/p.Val327Ala\                 [@B74][@B49]
                                                                                                                                    Intron 1 -588T\>A/Intron 2 321G\>T\     
                                                                                                                                    p.Ser78Gly/p.Arg144Gl\                  
                                                                                                                                    np.Arg56Ter/ Intron 1 -588T\>A^∗^\      

                            Complex III deficiency, tubulopathy, encephalopathy and liver failure                                   p.Ser277Asn\                            [@B21][@B22][@B31][@B66]
                                                                                                                                    p.Pro99Leu\                             
                                                                                                                                    p.Arg155Pro/p.Val353Met\                
                                                                                                                                    p.Arg45Cys/p.Arg56Ter\                  
                                                                                                                                    g.1181A\>G+g.1164C\>G/p.Arg56Ter^∗^\    

  **Pure Encephalopathy**   Complex III deficiency, encephalopathy, muscle hypotonia, psychomotor delay, pili torti                 p.Gly35Arg/p.Arg184Cys\                 [@B38][@B26]
                                                                                                                                    p.Arg73Cys/p.Phe368Ile\                 
                                                                                                                                    p.Arg183Cys/p.Arg184Cys\                

  **Milder Phenotypes**     Björnstad syndrome                                                                                      p.Arg183His\                            [@B38][@B69]
                                                                                                                                    p.Ile106Ter (IVS2+1G\>T)/p.Arg306His\   
                                                                                                                                    p.Arg306His/p.Arg114Trp\                
                                                                                                                                    p.Arg291Ter/p.Gln302Glu\                
                                                                                                                                    p.Tyr301Asn\                            

                            Muscle weakness, focal motor seizures, optic atrophy, long-survival                                     p.Gly129Arg\                            [@B73]

                            Behavioral alterations, hypomania/psychosis                                                             p.Gly129Arg\                            [@B2]
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The BCS1L protein contains several functional domains (**Figure [2](#F2){ref-type="fig"}**) necessary for its activity and stability ([@B28]; [@B18]; [@B63]): a transmembrane helix, a mitochondrial signal peptide plus an import auxiliary sequence, the AAA-domain and a Bcs1-specific sequence. Known pathological mutations are scattered throughout the different regions of the BCS1L sequence, with the exception of the transmembrane domain (**Figure [2](#F2){ref-type="fig"}**). In addition, some mutations have also been found in splice sites and in the 5′-UTR of the mature *BCS1L* mRNA (**Table [3](#T3){ref-type="table"}**). It is difficult to relate the position of the mutation to the pathological consequences at the biochemical and clinical levels. Most authors hypothesize that the clinical variability shown by the BCS1L mutated patients must be due to the nature of the amino acid substitution and its differential expression in different tissues ([@B38]; [@B45]; [@B66]). Different *BCS1L* mutations, investigated in six patient-derived skin cultured fibroblasts, were found to impair a number of different parameters, such as CIII activity and assembly, import of the protein into mitochondria, supramolecular associations of BCS1L, cell growth, shape of the mitochondrial network, ROS levels and antioxidant defenses, and apoptosis ([@B57]). Interestingly, the extent of the functional alterations in cultured cells correlated with the severity of the clinical presentation.

A consistent hallmark of GRACILE syndrome is liver iron overload, leading to the proposal of a role for BCS1L in cellular iron homeostasis ([@B74]). However, iron overload is present in some non-GRACILE cases and absent in others ([@B66]; [@B57]). To better characterize the pathophysiological consequences of the GRACILE mutation, a knock-in mouse has been created, being the only viable animal model of CIII deficiency reported to date ([@B48]). Homozygous mutant mice show growth retardation starting at 3 weeks and eventually die before 6 weeks from birth. They show progressive hepatopathy and profound CIII deficiency in liver, and to a lesser degree in heart and kidney as well. Interestingly, whilst the levels of Bcs1l in homozygous mutant liver and kidney were very low at any age, the amount of Uqcrfs1 incorporated into CIII~2~ progressively decreased over time, becoming almost undetectable just before death.

MZM1L (LYRM7)
-------------

Human *LYRM7*, located on chromosome 5q23.3 (OMIM 615831), encodes the LYR (leucine/tyrosine/arginine)-motif protein 7, a member of the Complex1_LYR-like superfamily ([@B7]). LYR motifs are the molecular signature of proteins that contain or assist in the delivery of Fe-S clusters ([@B50]). LYRM7 is highly homologous to the yeast protein Mzm1, which was originally described as necessary to maintain the mitochondrial pool of zinc ([@B8]), but was later demonstrated to be an assembly factor specific to the bc1 complex ([@B9]; [@B19]). The human protein can functionally complement the respiratory defect of a Mzm1-deleted yeast strain ([@B67]). Because of the similarities between both proteins, we proposed MZM1L as an alternative name for LYRM7 ([@B67]).

As already mentioned, the last step in CIII assembly involves the incorporation of Rip1/UQCRFS1 protein into CIII in the inner mitochondrial membrane after it has been imported into the matrix, processed to a mature form and endowed with a 2Fe-2S cluster cofactor ([@B35]). The yeast and human proteins work as a stabilizing chaperone of the Rieske protein in the mitochondrial matrix, interacting with its C-terminal domain and holding it there prior to its translocation to the inner mitochondrial membrane and incorporation to CIII ([@B19]; [@B67]). A possible role for LYRM7 in Fe-S cluster delivery is also suggested by its interaction with the HSC20 cochaperone ([@B50]).

Genetic screening of *LYRM7* in unresolved cases of CIII deficiency, led to the identification of a homozygous c.73G\>A transition, which predicts a p.Asp25Asn amino acid change. Yeast studies confirmed the pathogenicity of the mutation ([@B40]). The affected child was born to Moroccan healthy first cousins. Her development was normal until 20 months of age, when she presented progressive weakness with anemia associated with low plasma iron. A month later, during a febrile infection, she developed severe encephalopathy and metabolic acidosis. Severe psychomotor regression persisted until 28 months of age, when she died of respiratory failure.

To further characterize the molecular function of MZM1L, we performed RNAi experiments in HeLa cells (**Figure [3A](#F3){ref-type="fig"}**). Similar to the Mzm1 deletion yeast strain ([@B9]), low levels of MZM1L caused a decrease in the total amount of UQCRFS1 (**Figure [3A](#F3){ref-type="fig"}**), while UQCRC2 was unaffected. However, in normal culture conditions, the amount of UQCRFS1 incorporated into CIII~2~ and the CIII enzyme activity was the same as in control cells (**Figures [3B,C](#F3){ref-type="fig"}**). Only by exposing the interfered cells to heat stress (incubation at 42^∘^C for 24 h) was the reduced CIII assembly and activity manifested (**Figures [3B,C](#F3){ref-type="fig"}**). Thus, the absence of MZM1L makes UQCRFS1, unstable but only the fraction residing in the matrix that has not been assembled into the complex. These results support the idea that MZM1L is necessary to stabilize UQCRFS1 in the matrix but is not involved in its translocation, which is virtually normal even when MZM1L is absent. Similar to Mzm1-deficient yeast ([@B9]), the phenotype is thermo-sensitive, probably because at high temperatures the unassembled Rieske protein is more prone to degradation and/or aggregation ([@B19]). This could explain why the clinical course drastically worsened in the LYRM7 mutated patient after a febrile episode ([@B40]).

![**MZM1L RNA interference experiments in HeLa cells**. Five different shRNA sequences cloned in the pLKO.1 lentiviral vector (TRCN0000064433-37), purchased from the MISSION® shRNA Library (Sigma-Aldrich) were stably transduced. **(A)** The steady state levels of the indicated proteins were quantified by SDS-PAGE, Western blot and immunodetection with specific antibodies: anti-LYRM7 (MZM1L) and Actin (Sigma-Aldrich) and UQCRFS1 and UQCRC2 (Mitosciences-Abcam). Actin was used as the normalizer/loading control. The shRNA sequences\...33, ...36, and ...37 were the most efficient in knocking down MZM1L expression. **(B)** Blue-Native PAGE, Western blot and immunodetection analysis of knocked down and control digitonin-treated cells ([@B60]) grown either at 37^∘^C or at 42^∘^C for 24 h. Anti-MTCO1 was from Mitosciences-Abcam. **(C)** Spectrophotometric CIII and CIV enzyme activities of the RNAi and control cells grown either at 37^∘^C or at 42^∘^C for 24 h. ^∗^*p* \< 0.05 according to the ANOVA *Post-Hoc* LSD test (SPSS 16.0 software for Windows).](fgene-06-00134-g003){#F3}

UQCC2
-----

Sequencing the "MitoExome," i.e., through the specific capture of both mtDNA and ∼1,000 nuclear genes encoding (part of) the mitochondrial proteome ([@B16]), a mutation in *UQCC2* (*C6orf125*; OMIM 614461) was discovered in a patient with profound CIII deficiency ([@B72]). This subject also presented secondary reduction in CI and CIV activities. The mutation, found in homozygosis in exon 2 (c.214-3C\>G), caused altered splicing of the transcript and the absence of the protein ([@B72]). The consequence for the patient, a boy born to consanguineous Lebanese parents, was severe metabolic acidosis documented 12 h after birth. He also had dysmorphic features, delayed neurological development and sensorineural hearing impairment, and later developed autistic features and aggressive behavior. He was alive at 9 years of age when clinical follow-up was lost.

UQCC2 is the ortholog of yeast Cbp6, which interacts with Cbp3, homolog to human UQCC1. UQCC2 and UQCC1 were also shown to interact, because the presence of one is required for the stability of the other ([@B72]). The two proteins co-migrate in Blue-Native gels (**Figure [4](#F4){ref-type="fig"}**), showing a pattern very similar to the yeast proteins ([@B32], [@B34]; [@B37]). In yeast mitochondria, the Cbp3--Cbp6 complex binds to the mitochondrial ribosome exit tunnel where it is necessary for the efficient synthesis of cytochrome b and the first steps of bc1 complex assembly ([@B32], [@B34]). Furthermore, the Cbp3--Cbp6 complex regulates cytochrome b synthesis linking it to its assembly, because once the translation of cytochrome b is completed, the Cbp3--Cbp6 complex remains bound to the peptide in the mitochondrial inner membrane while another protein, Cbp4, is recruited. Unless other structural subunits (Qcr7 and Qcr8) bind to cytochrome b, the Cbp3--Cbp6 complex is sequestered and cannot bind again to the ribosome to activate the synthesis and release of new cytochrome b ([@B32], [@B34]; [@B37]).

![**Co-migration of human UQCC1 and UQCC2 in Blue-Native PAGE**. Mitoplasts from HeLa cells were solubilized using either 1% dodecylmaltoside (DDM) or 2% digitonin and then run through a NativePAGE^TM^ 3--12% native gel (Life Technologies). After the lanes were excised, treated with denaturing solution and run through a NuPAGE^TM^ 4--12% Bis-Tris denaturing gel (Life Technologies). The gels were then transferred to PVDF membranes and immunoblotted with antibodies recognizing UQCC1 (UQCC) and UQCC2 (MNF1) both from Abcam.](fgene-06-00134-g004){#F4}

Similar to Cbp6-deleted yeast model, UQCC2-deficient cells show greatly reduced MT-CYB synthesis, whereas the amount of CIII is recovered when the wild-type protein is expressed ([@B72]). The same report demonstrated the physical interaction between UQCC2 and newly synthesized MT-CYB.

UQCC3
-----

Bioinformatics analyses predicted that the protein encoded in the *C11orf83/UQCC3* gene might be the ortholog of the yeast protein Cbp4, another cytochrome bc1 complex assembly factor ([@B76]). Mutational screening in a patient showing isolated CIII deficiency in skeletal muscle, revealed the presence of a homozygous c.59T\>A mutation producing a p.Val20Glu amino acid change, in a position where there are only hydrophobic residues in other metazoan homologs. Both parents were consanguineous, and heterozygous for the mutation. The patient showed very early-onset symptoms, presenting hypoglycemia and severe lactic acidosis already in the first day of life. She suffers from muscle weakness from birth, with severely delayed psychomotor development. Biochemically, cultured fibroblasts showed very reduced levels of assembled CIII and low MT-CYB synthesis and stability.

Yeast Cbp4 assists the first steps of CIII assembly, binding to the cytochrome b-Cbp3-Cbp6 intermediate once it is released from the mitoribosome, but is not required for cytochrome b translation ([@B34]). These interactions can occur only once the b~L~ site of cytochrome b has been hemylated ([@B37]).

There are strong indications that the mutation found in the reported patient is pathogenic: the type of amino acid change, which makes the protein unstable; its absence in a number of controls; and segregation with the disease ([@B76]). Also, the prediction of UQCC3 as being the Cbp4 ortholog explains the CIII deficiency. However, UQCC3 is shorter than Cpb4 (93 vs. 147 amino acids) and their C-terminal sequences are not homologous. Furthermore, human UQCC3 presents a different topology inside mitochondria and is not able to complement a Cbp4-deficient yeast strain ([@B76]). In addition, knocked-down expression by RNAi in control cells did not affect CIII assembly or activity and the patient's CIII defect in fibroblasts could not be rescued by expression of exogenous wild-type recombinant UQCC3.

Concluding Remarks
==================

Although the genetic definition of CIII deficiency has remarkably expanded in the last 5 years, ∼50% of the cases remain genetically unsolved. This is likely due to a still sketchy understanding of the assembly process of CIII and limited knowledge of the specific assembly factors required for this process to be completed. As stated above, the model currently favored for CIII assembly (**Figure [1](#F1){ref-type="fig"}**) is based on studies in *S. cerevisiae,* but several lines of evidence supports the idea that a very similar process occurs in humans ([@B26]; [@B67]; [@B72]). Nevertheless, even in yeast mechanistic understanding has been achieved only for the initial and final steps of the process, i.e., the events just following the *de novo* synthesis of cytochrome b ([@B33]; [@B32], [@B34]; [@B37]) and the incorporation of the Rieske protein which rapidly leads to assembly completion ([@B9]; [@B75]; [@B19]). Whilst OXPHOS accessory proteins that directly interact with structural subunits seem to be conserved from yeast to humans, other factors, for instance TTC19, do not appear to have yeast orthologs ([@B30]). This reflects evolutionary divergence as well as the differences in the mitochondrial genetic system and MRC organization between yeast and metazoans. The most obvious dissimilarity is the presence in mammals of the multimeric complex I and its interaction with CIII and CIV, to form the so-called supercomplexes or respirasomes ([@B1]; [@B58]; [@B47]). The easy genetic manipulation and the metabolic flexibility of *S. cerevisiae*, a facultative fermentative organism, make it an extremely useful model to study OXPHOS biogenesis. By genetic data mining and phylogenetic analysis, yeast factors have been key to discover human orthologs and model in yeast some of the mutations found in patients ([@B12]; [@B54]), including assembly factors and chaperones such as BCS1L ([@B21]; [@B74]; [@B26]; [@B63]; [@B54]) and MZM1L ([@B40]).

A next, formidable challenge will be to unravel the mechanisms and factors specific to mammalian CIII biogenesis. In this respect, the genetic characterization of CIII defective subjects, by NGS technology, and new tools offered by proteomic techniques applied to human cells and animal models will be fundamental to make progress in this field.

Conflict of Interest Statement
==============================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

We are very grateful to Caterina Garone (MRC-Mitochondrial Biology Unit) and Dennis R. Winge (University of Utah) for critically reading the manuscript and to Daniele Ghezzi (Istituto Neurologico "C. Besta") for sharing information about *TTC19* mutations. Our research was funded by a "Miguel Servet" Grant (CP09/00156) from the Instituto de Salud Carlos III (Ministerio de Economía y Competitividad), "Marie Curie" European Reintegration Grant (PERG04-GA-2008-239372) and Association Française contre les Myopathies Research Grant (AFM 16086) to EF-V. and by the Medical Research Council, UK.

[^1]: Edited by: *Tiziana Lodi, University of Parma, Italy*

[^2]: Reviewed by: *Saima Siddiqi, Institute of Biomedical and Genetic Engineering, Pakistan; Vineta Fellman, Lund University, Sweden*

[^3]: ^†^Former address: *Erika Fernández-Vizarra, Unidad de Investigación Traslacional, Hospital Miguel Servet, Instituto Aragonés de Ciencias de la Salud, Zaragoza, Spain*

[^4]: This article was submitted to Genetic Disorders, a section of the journal Frontiers in Genetics
